CAPR Deadline Approaching: BFA Law Notifies Capricor Therapeutics Investors Who Suffered Losses of Ongoing Securities Fraud Class Action and Upcoming September 28 Deadline
Bleichmar Fonti & Auld LLP notified Capricor Therapeutics investors of a class action lawsuit alleging securities fraud related to clinical data for the drug candidate Deramiocel. The complaint cites a 64.5% stock drop on July 27, 2026, and a subsequent 36% drop following FDA concerns over statistical analysis plans and advisory committee votes.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.